Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Other Operating Expenses (2017 - 2021)

Historic Other Operating Expenses for Neurocrine Biosciences (NBIX) over the last 11 years, with Q3 2021 value amounting to $4.2 million.

  • Neurocrine Biosciences' Other Operating Expenses fell 9653.47% to $4.2 million in Q3 2021 from the same period last year, while for Dec 2021 it was $15.2 million, marking a year-over-year decrease of 9562.97%. This contributed to the annual value of $882.9 million for FY2020, which is 14407.17% up from last year.
  • Latest data reveals that Neurocrine Biosciences reported Other Operating Expenses of $4.2 million as of Q3 2021, which was down 9653.47% from $8.1 million recorded in Q2 2021.
  • Over the past 5 years, Neurocrine Biosciences' Other Operating Expenses peaked at $176.1 million during Q4 2020, and registered a low of $61000.0 during Q2 2017.
  • In the last 5 years, Neurocrine Biosciences' Other Operating Expenses had a median value of $2.6 million in 2019 and averaged $32.6 million.
  • Its Other Operating Expenses has fluctuated over the past 5 years, first skyrocketed by 1192610.53% in 2019, then plummeted by 9816.19% in 2020.
  • Over the past 5 years, Neurocrine Biosciences' Other Operating Expenses (Quarter) stood at $760000.0 in 2017, then surged by 101.84% to $1.5 million in 2018, then skyrocketed by 6030.25% to $94.0 million in 2019, then surged by 87.26% to $176.1 million in 2020, then crashed by 97.61% to $4.2 million in 2021.
  • Its Other Operating Expenses stands at $4.2 million for Q3 2021, versus $8.1 million for Q2 2021 and $2.9 million for Q1 2021.